The New York Times
By Andrew Pollack
February 23, 2016
The drug ZMapp, viewed as perhaps the most promising potential treatment for Ebola, seemed to prevent death from the disease in its first rigorous clinical trial, researchers reported on Tuesday.
However, they said, the results were not conclusive, probably because the Ebola outbreak in West Africa ended before enough patients could be enrolled in the study.
Read the full article in the New York Times